By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biohaven Pharma 



New Haven  Connecticut    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board 3/8/2017 9:52:13 AM
Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board 3/7/2017 7:34:58 AM
Biohaven Enrolls First Patient In Pivotal Trial Of BHV-4157 In Patients With Hereditary Spinocerebellar Ataxia 12/22/2016 12:35:10 PM
Biohaven' BHV-0223 Is Granted Orphan Drug Designation In The Treatment Of Amyotrophic Lateral Sclerosis 12/9/2016 7:19:07 AM
Biohaven Announces Orphan Drug Designation Request Granted For Bhv-0223 In The Treatment Of Amyotrophic Lateral Sclerosis ("Als") 12/8/2016 8:12:14 AM
Biohaven Secures $80 Million In Oversubscribed Private Financing To Advance Phase 3 Clinical Trials 11/1/2016 8:30:16 AM
Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment 10/3/2016 7:22:21 AM
Biohaven Commences Clinical Testing Of BHV-4157 7/20/2016 6:59:33 AM
//-->